INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is recognized as one of the most common cause of chronic liver diseases in Western countries, as well as in Korea. [1] [2] [3] NAFLD is considered liver manifestation of insulin resistance (IR) and metabolic syndrome since it is closely associated with obesity, hypertension and dyslipidemia. [4] [5] [6] NAFLD is a condition of fat overaccumulation in the liver and clinicohistologic phenotype of NAFLD extends from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) and/or fibrosis. 7 NASH can progress to cirrhosis 8 or liver failure and increase the risk of hepatocellular carcinoma and induce liver related mortality. [8] [9] [10] [11] [12] [13] [14] Although a liver biopsy is considered as a gold standard for the diagnosis and estimation of the activity of NAFLD, it is an invasive procedure with a considerable cost. Because fat accumulation and inflammation of NAFLD are more heterogeneous than those of chronic hepatitis C, it is more prone to the sampling errors. 15 Steatohepatitis is not merely the presence of steatosis and inflammation but a specific histopathologic entity (macrovesicular steatosis, inflammation and ballooned hepatocyte and/or MalloryDenk bodies). 16 NAFLD activity assessment using a biopsied sample only may lead to inadequate evaluation. Therefore, various noninvasive laboratory tests or imaging studies for evaluating the extent of fat accumulation, the presence of necroinflammation and the stage of fibrosis has been studied to avoid unjustified liver biopsy. Numerous biomarkers have been investigated in order to discriminate NASH from simple steatosis. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] However, there is no unique biomarker to meet the requirements sufficiently. Hepatocyte apoptosis is typically increased in subjects with NASH, not in those with NAFL. 28 Cytokeratin 18 (CK-18) is the major intermediate filament protein in the liver resulting in the characteristic structural changes of apoptosis. 29 Caspase generated CK-18 fragments were increased in patients with NAFLD compared with healthy age-matched controls, and plasma levels correlated with expression levels in the liver. 30 The aims of this study are (1) to identify the useful clinical parameters of a noninvasive approach to distinguish NASH from NAFL; and (2) to determine whether these levels would be related to the severity of the liver injury in patients with NASH. All enrolled patients were Koreans, and the study protocol was approved by the review board at each participating institution. All subjects gave consents prior to the participation.
PATIENTS AND METHODS

Patients
Clinical assessment
The medical history, including co-morbid illness (such as hypertension or diabetes) and drug/herb intake, anthropometric, laboratory and clinical data were collected from all patients at the same day of liver biopsy.
Body mass index (BMI) was calculated as body weight in kilograms divided by body height in square meters (kg/m 2 ). Waist circumference was measured in a standing position at a level of the umbilicus with the tape all around the body in the horizontal position. Venous blood samples were taken in the morning after a 12 hours overnight fasting on the day of liver biopsy. The laboratory evaluation in all patients included a blood cell count and the measurement of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), total cholesterol, triglyceride (TG), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, albumin, glucose, C-reactive protein (CRP), immunoreactive insulin, ferritin, and fragmented CK-18. IR was evaluated according to homeostatic model assessment (HOMA), 31 as fasting serum insulin (in µIU/mL) multiplied by fasting serum glucose (in mg/dL), divided by 405. The diagnosis of metabolic syndrome 32 was carried out according to the joint statement of the International Diabetes Federation, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, and International Association for the Study of Obesity, and based on the presence of three or more the following criteria: (1) central obesity (waist circumference ≥90 cm in men and ≥80 cm in women), (2) TG >150 mg/dL, (3) reduced HDL-cholesterol (<40 mg/dL in men and <50 mg/dL in women), (4) blood pressure ≥130/85 mmHg and (5) fasting plasma glucose ≥100 mg/dL, or drug treatment for the above metabolic abnormalities.
Histologic evaluation
All the patients underwent an ultrasonic guided percutaneous liver biopsy using a 16-gauge needle (Acecut ® ; TSK Laboratory, Tochigi, Japan) under local anesthesia. Liver biopsy specimens were fixed in 10% buffered formalin, embedded in paraffin and stained with hematoxylin and eosin, Masson-trichrome, and/or reticulin stain. The slide were reviewed in conference by both experienced hepatopathologists (ESJ and HKK) who were blinded to all clinical, demographic and laboratory information, the diagnosis of NASH were made by consensus. Histological grading and staging of NAFLD were scored semiquantitatively according to the original criteria for NAFLD subtypes, 9, [33] [34] [35] and NAFLD histologic activity score (NAS) system. 16 According to the original criteria, the NAFLD was histologically categorized into four subtypes 9 : (1) steatosis alone (NAFLD type 1),
(2) steatosis with lobular inflammation only (NAFLD type 2), (3) steatosis with hepatocellular ballooning (NAFLD type 3), or (4) steatosis with Mallory-Denk bodies or fibrosis (NAFLD type 4). NAFLD subtypes 3 and 4 were considered to represent NASH. 34 Histologic finding with stage 2 or above fibrosis were also defined as NASH. 21 The NAS identified the degree of steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2). 16 The NAS was the sum of above numerical pathologic scores and ranged from 0 to 8. The stage of fibrosis was scored on a fivepoint scale, as follows: stage 0=no fibrosis, stage 1=perisinusoi-dal or periportal fibrosis, stage 2=perisinusoidal and portal/periportal fibrosis, stage 3=bridging fibrosis, and stage 4=cirrhosis.
16
Caspase generated CK-18 fragment
Serum samples were obtained from the patients on the same day of the liver biopsies and stored at -80 o C until just before analysis. The levels of the apoptosis-associated CK-18 in sera the were measured by the M30-Apoptosense enzyme-linked immunosorbent assay (ELISA) kit (PEVIVA AB, Bromma, Sweden). 19, 36 All assays were performed in duplicate and the absorbance was determined by using a microplate reader (Molecular Devices M2, Sunnyvale, CA).
Statistical analysis
Continuous variables were expressed as means±standard deviation. Categorical data analysis was performed using the Chisquare test and Fisher's exact test, as appropriate. Quantitative data analysis was performed using independent t-test and oneway analysis of variance for normal distributional data, or MannWhitney U test and Kruskal-Wallis test for non-parametric data. Spearman's correlation analysis or pairwised correlation analysis was used to assess relationship between CK-18/ferritin and hepat- 
RESULTS
Patients' characteristics
There were 108 patients recruited in this study. The baseline clinical and laboratory characteristics of the patients are described in Table 1 With NAS system, there were 9 patients (8.3%) with "NAS ≤2", 54 (50%) with "NAS: 3-4", and 45 (41.7%) with "NAS≥5", respectively ( Table 2 ). The numbers of patients with fibrosis 0 or 1 are 73. Thirty-six (49.3%) in this group are NAFLD subtype 1 or 2 ( Table 2) .
In NASH group (NAFLD subtype 3 or 4), none had below 3 points of NAS, 27 (40.3%) had 3-4 points of NAS, and 40 (59.7%) had over 4 points of NAS. In non-NASH group (NAFLD subtype 1 or 2), 9 (22.0%) had below 3 points of NAS, 27 (65.9%) had 3-4 points of NAS, and 5 (12.2%) had over 4 points of NAS (Fig. 1) . And also, 27 (42.9%) of patients below 5 points of NAS are in group of NAFLD subtype 3 or 4 and 5 (11.1%) of patients above 4 points of NAS are in group of NAFLD subtype 1 or 2, respectively (Fig. 1) .
Diagnosis of NASH using serum biomarkers in NAFLD patients
CK-18 level had positive correlation with systolic blood pressure, AST, ALT, HDL-cholesterol, ferritin, lobular inflammation, ballooning, fibrosis, NAS and NAFLD subtype (Table 3 and Fig. 2 ). Serum ferritin level had positive correlation with insulin, HOMA-IR, AST, ALT, fibrosis and NAS (Table 3 and Fig. 3 ). Serum ferritin levels showed weaker positive correlation with histopathologic characteristics including NAS (r=0.258) and stage of fibrosis (r=0.272) than fragmented CK-18, respectively. The serum CK-18 level was significantly higher in NAFLD subtype 3 or 4 group than that of NAFLD subtype 1 or 2. However, the ferritin level was not significantly elevated in this group (Table 1) .
A fragmented CK-18 cutoff value of 235.5 U/L calculated using the receiver operating characteristic curve showed a sensitivity of 69.0%, a specificity of 64.9%, and positive and negative predict values (PPV and NPV) of 75.5% (95% confidence interval [CI] 62.4-85.1) and 57.1% (95% CI 42.2-70.9), respectively, for the diagnosis of NASH. Additional measurement of ferritin to CK-18 improved a specificity of 85.2% and a PPV of 92.6% (95% CI 82.4-97.1), respectively (Table 4) .
DISCUSSION
Since the progression is very different depending on NAFLD subtype, the diagnosis of NASH is important to predict prognosis and to identify candidates who require treatment. Although there has been several previous studies investigating CK-18 as a biomarker to replace biopsy, this research provides an evidence that 16 The NAS could provide a disease activity score for patients who most likely have NASH. 16 The NAS has reasonable inter-rater reproducibility and represent changes more sensitively allowing evaluating of therapeutic response or natural course possible. However, this system has not been validated to see if the system could predict progression to cirrhosis or liver related mortality. 16, 35 Even though several new diagnostic criteria for NASH has been developed, the original criteria for NAFLD subtypes demonstrated the best predictability for liver-related mortality in patients with NAFLD the most effectively. 33 Thus we decided to use the original diagnostic criteria in order to diagnose NASH and to take NAS system as an auxiliary test. In previous study, 16% of biopsies did not meet NASH criteria yet had a NAS ≥5, 37 16 In the present study, we assessed histology activity with original criteria along with NAS. There is no patient scored below NAS 3 in group of NAFLD subtype 3 or 4. On the other hand, thirty two patients from NAFLD subtype 1 or 2 scored 3 or greater points under NAS system. The discordance rate between the original criteria and NAS in the diagnosis of NASH was 29.6%. Elevation of aminotransferase level can be a clue for diagnosis of NAFLD. However, it has some of its own weaknesses in the diagnosis of NAFLD. 1) It does not assess the degree of lipid accumulation, 2) It does not provide a cause of liver disease and 3) It does not discriminate between NASH and NAFL. 6 Apoptosis of hepatocytes plays an important role in the progression of the NASH and the liver injury. Hepatocytes containing Mallory bodies are likely to undergo apoptosis. The major components of Mallory body include CK-8 and 18, ubiquitin and heat shock proteins 70 and 90. 38 The main reason for the results being different from our studies is that they classified the patients according to the consensus of the NASH CRN Pathology Committee Criteria, while we used the original NAFLD criteria. Furthermore, by discerning NAFLD sub- http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.2.120 type 1 & 2 and NAFLD subtype 3 & 4, we were able to demonstrate some different qualities from the existing studies which only distinguished simple steatosis and NASH. Also, patients with morbid obesity were included in some studies used in the meta-analysis. Though CK-18 is a very promising biomarker for the determination of NASH, cutoff level to diagnose NASH has not been confirmed and assay for CK-18 is not commercially available as yet. Therefore, there are some obstacles to be overcome in order to apply CK-18 in the clinical practice. 42 An elevation of serum ferritin concentrations in the absence of iron overload, can be resulted from inflammation, liver necrosis and alcohol abuse. 43 As for NAFLD, increased serum ferritin levels are noted in patients with diabetes mellitus 44 and NASH. 45 Elevated ferritin levels is considered to be a representation of the metabolic syndrome and of hepatic damage due to inflammatory cytokine activation. 46 Even though, there is no solid conclusion whether increased ferritin levels are associated with fibrosis or presence of NASH in the patients with NAFLD, serum ferritin is a discriminant marker for both fibrosis and inflammation, and an independent factor associated with NASH in histologically proven NAFLD patients. 45, 47 Furthermore, serum ferritin can be useful for selecting patients that should undergo liver biopsy among the patients with NAFLD. 45 This study has some limitations. First, histologic findings of the liver biopsy were used as the gold standard. Sampling variability or interpretation error could be present. Nevertheless, liver biopsy is currently the only reference standard, and the slide were reviewed in conference by two experienced hepatopathologists. Second, we could not compare our cohort with non-NAFLD control cohort. Using the viral hepatitis cohort as the control is not recommended due to the variety of confounding factors that may complex the viral hepatitis pathology. Moreover, obtaining normal liver tissue without any overt problems is next to impossible and also unethical. Third, the patients were recruited in a tertiary academic hospital and all patients had liver biopsy performed. This meant patients with more severe disease activity than NAFLD patients in the general population may have been included in our cohort. Unfortunately, we didn't get HFE genotyping to exclude primary hemochromatosis and we could check fasting transferrin saturation in only a limited number of patients. Despite several limitations, as far as we know, this is the first prospective study recruiting to biopsy proven NAFLD in large scale in Korea, we are planning to have a further observational study with this cohort.
In this prospective cohort study, measurement of serum CK-18 and ferritin levels helped to distinguish NASH from simple steatosis, and to assess the fibrosis in Korean patients with biopsy proven NAFLD. We need further evaluation on whether the combined measurement of serum CK-18 and ferritin levels improves the diagnostic performance of NASH. To confirm these results, larger validation analyses and longitudinal prospective studies are needed.
